Patient-derived organoids for precision cancer immunotherapy

Running title: Immune Complex Organoid

Authors: Mikaela Grönholm$^{1,2,3,4}$, Michaela Feodoroff$^{1,2,4,5}$, Gabriella Antignani$^{1,2,4}$, Beatriz Martins$^{1,2,4}$, Firas Hamdan$^{1,2,4}$ and Vincenzo Cerullo$^{1,2,3,4,6}$*

Affiliations:

1Laboratory of Immunovirotherapy, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5E, 00790 Helsinki, Finland
2Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Finland
3ICAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Finland
4TRIMM, Translational Immunology Research Program, University of Helsinki, Finland
5FIMM, Institute for Molecular Medicine Finland, Helsinki Institute for Life Sciences (HiLIFE), University of Helsinki, Helsinki, Finland.
6Department of Molecular Medicine and Medical Biotechnology and CEINGE, Naples University Federico II, 80131, Naples, Italy

*Corresponding author: Vincenzo Cerullo
email: vincenzo.cerullo@helsinki.fi
Phone:+358294159328

Conflict of Interest: Vincenzo Cerullo is a co-founder and shareholder at VALO therapeutics. NO related to this work. The other authors declare no conflict of interest.

Abstract

Cancer immunotherapy has revolutionized the way tumors are treated. Nevertheless, efficient and robust testing platforms are still missing, including clinically relevant human ex vivo tumor assays that allow pre-treatment testing of cancer therapies and selection of the most efficient and safe therapy for a specific patient. In the case of immunotherapy, this testing platform would require not only cancer cells but also the tumor microenvironment, including immune cells. Here we discuss the applications of patient-derived tumor organoid cultures and the possibilities in using complex
immune-organoid cultures to provide pre-clinical testing platforms for precision cancer immunotherapy.

**Cancer immunotherapy**

Cancer immunotherapy exploits the immune system to fight the disease. Our immune system already has a complex series of mechanisms to detect and eradicate cancer cells, but many on them are inactivated during cancer progression (1). There are several ways immunotherapy can aid the immune system in recognizing the tumor, initiating an immune response or boosting an existing one against the neoplastic cells. Non-specific immunotherapy can strengthen the overall activity of the immune system by introducing adjuvants such as cytokines or other cell signalling molecules. Specific immunotherapy, on the other hand, requires the identification of one or more tumor targets that the immune response can turn against to induce an antigen-specific immune response. This can be achieved using anti-cancer vaccines, dendritic cell (DC) therapy or oncolytic viruses, which engage the host immune system. Immunotherapy can also target cancer cells through the administration of immune system components that either act directly on the tumor to kill it or unleash the effect of pre-existing immunity. These include T cell and antibody-based therapies. For a more extensive review on different cancer immunotherapies, see (2)(3). Outstanding results have been observed in some patients treated with cancer immunotherapies, especially using immune checkpoint inhibitors and chimeric antigen receptor (CAR) cells, indicating that it is possible to restore the body’s defense against a tumor (4)(5). However, to date, many immunotherapies have demonstrated success in only a selected group of cancers and patients. The lack of efficacy can be due to poor immunogenicity of the tumor, immune suppression mediated by the tumor and the tumor microenvironment (TME) or tumor evasion.

In contrast to chemotherapies, immunotherapies lack a proper model to test their efficacy. Murine models, that are very helpful for studying classic drug efficacy, are not relevant for all forms of
immunotherapy as the murine immune system differs too much from the human. Hence, there is a need to find alternative models that recapitulate the human disease while conserving all the peculiarities of the human immune system. Human cell lines and patient derived tumor xenografts (PDTX) have been used as models, but tumor organoids and complex tumor immune-organoids might represent the new frontier.

**Patient-derived organoids**

Patient-derived tumor organoids (PDTOs) have become a favourable model for cancer treatment testing and prediction. Organoids are three-dimensional multicellular structures that can be cultured to resemble the original tissue upon embedment in a 3D matrix (6)(7). In 2009, Sato et al. described the generation of organoids from mouse intestinal stem cells (8), which formed the starting point for other organoid culture protocols of multiple mouse and human epithelia. Organoids contain self-organizing capacities and can be grown from pluripotent embryonic stem cells or induced pluripotent stem cells (iPSCs) to mimic embryonic developmental processes, or from adult stem cells to model tissue homeostasis or disease progression. The development of PDTO cultures presented a novel approach to model human cancers *in vitro*. So far, tumor tissue from several tumor types has successfully been cultured as organoids, the majority of which originate from epithelial cancers (9).

In contrast to organoids, spheroids are clusters of cells which do not self-assemble or regenerate. Cell aggregation is prompted in low-adhesion culture conditions, which does not require a scaffold, and result in sphere-shaped 3D structures.

To culture tumor organoids, cells derived from tumor tissue are dissociate physically or enzymatically, embedded in an extracellular matrix and grown in the presence of culture media containing specific growth factors and/or inhibitors required by that tissue (10). The choice of biological or synthetic scaffold mimicking the extracellular matrix (ECM) depends on the tissue and can have different porosity, permeability, surface chemistry and mechanical characteristics. Hydrogels such as Matrigel matrix or collagen I have been successfully used in many
organoid cultures. Matrigel is a basement-membrane matrix extracted from mouse sarcoma. It is not that well defined, display batch-to-batch variability and cannot be used for organoid expansion in animal-free or GMP-compliant systems. Synthetic scaffolds with precise ECM composition could overcome these limitations providing well-defined, reproducible, xenogenic-free alternatives (11)(12). Tumor organoids display variable growth rates and reach different sizes (13)(14). This depends on the chosen culture system but is also affected by the viability and amount of necrosis in the original tumor tissue, whether samples were taken pre- or posttreatment and the sample processing time and technique.

Tumor organoids have several advantages over pre-existing tumor models. Although 2D cell lines are cost-efficient and easy to culture, observe and measure, they lack the complexity of tumors. Moreover, PDTOs better maintain key genetic and phenotypic features from their parental tumour (15). This was shown for lung and breast cancer organoids, which successfully retained the histopathological characteristics and recapitulated the genomic landscape of the cancer subtypes, and their response to different drugs correlated with the genomic alterations in the tumors (16)(13). Nevertheless, culture stability may vary between tumor-types and culture conditions. Therefore, characterizing and following the genotype and phenotype of the organoid over time is critical to avoid culturing only one or a few dominant clones from the heterogenous tumor tissue and to ensure that the model is representative of the original tumor.

Human tumors engrafted in mouse hosts, PDTXs, retain therapeutically relevant genomic aberrations found in the original tumor, but in contrast to PDTXs, PDTOs can be expanded with high efficiency, cultured for long term and eventually cryopreserved. These features allow generating tumour organoid biobanks and provide a platform for high-throughput drug screens at a lower cost than animal models and with fewer ethical concerns (15)(13). Indeed, PDTOs have been used as preclinical models to predict response to anti-cancer agents (17)(18)(19). Drug screening on specific patient’s tumors permit personalized therapy predictions as PDTOs can be generated and expanded.
in vitro in a timeline compatible with therapeutic decision-making. Screening for compounds that selectively kill tumor cells and do not show toxicity on non-cancerous cells is made possible by testing both tumor and normal tissue-derived organoids. Furthermore, research is underway to create patient-specific in vitro organ models using iPSCs for personalized toxicity screening and adverse drug reaction characterization (20).

Complex organoids

Although tumor organoids can help to accurately predict a patient’s response to therapy and choose personalized treatment strategies, tumor organoids do not fully recapitulate the tumor microenvironment. In addition to transformed cells, established neoplasms contain abundant and heterogeneous non-transformed components of stroma, fibroblasts, endothelial and immune cells. The lack of immune components limits the value of organoids as platforms to test immunotherapy. Nevertheless, attempts to grow more complex organoids are underway (Figure 1).

Adding immune components

There are two different approaches to organoid-immune cell co-cultures; retaining and expanding endogenous immune cells within tumor organoids or the addition of immune cells to organoids.

One of the first papers describing the expansion and activation of endogenous immune cells within organoid cultures was done with human epithelial breast tissue (21). The authors cultured ductal epithelial organoids and demonstrate the presence of immune cell populations within the culture, with 90% of the CD45+ immune cell population being CD3+ T cells characteristic of intraepithelial lymphocytes. In another study, murine- and patient-derived organotypic tumor spheroids cultured in a collagen matrix for up to 9 days in a microfluidics device were able to retain autologous lymphoid and myeloid cell populations (22).

The air-liquid interphase culturing system (ALI) can maintain native stromal and immune components. Tumor organoids are embedded in a collagen gel where one surface is in contact with
the liquid culture and one is exposed to air. Using the ALI-culture method with human lung cancer and colorectal cancer (CRC) organoids, endogenous CD45+ immune cell populations survived for more than 10 days, although there was a marked reduction in the number of CD3+ cells (23). In a more recent large-scale study, the ALI-method was used to culture patient-derived organoids from different surgically resected tumors types (24). Cultures retained the tumor epithelium and its stromal microenvironment with fibroblasts and immune cells including tumor-associated macrophages, cytotoxic T lymphocytes (CTLs), T-helper cells, B-cells, natural killer (NK) cells and NK T cells for 30 days. In addition, these cultures recapitulated the T cell receptor (TCR) heterogeneity of the T-cells found in the original tumors.

The other approach to immune-organoid cultures encompasses expanding organoids and immune cells separately and then establishing a co-culture with both components. Dijkstra et al cultured CRC and non-small-cell lung carcinoma (NSCLC) human organoids derived from tumor biopsies or surgical resections in Geltrex basement membrane together with expanded autologous peripheral blood mononuclear cells (PBMCs) (25). PBMCs were stimulated weekly with autologous tumor organoids in the presence of IL-2, and plate bound anti-CD28 and anti-PD-1 antibodies. This co-culture could be used to enrich tumor-reactive CD8+ populations from the peripheral blood of patients. Another co-culture contained pancreatic tumor organoids derived from surgical specimens grown in Matrigel, with patient-matched cancer associated fibroblasts (CAFs) and peripheral blood lymphocytes (26). T-cells remained viable after 6 days in culture. Tumor-dependent lymphocyte infiltration and activation of myofibroblast-like CAFs were observed in these models. Finally, a patient-derived gastric organoid co-culture grown in Matrigel with dendritic cells (DCs) and CTLs purified from the patient’s blood, was used to model the protective mechanism of increased PD-L1 expression in response to *H. pylori* infection (27). Inhibition of PD-L1/PD-1 interactions induced proliferation of CTLs within the co-culture and organoid killing.
Although there are successful examples of immune-organoids modeling the complex interactions between the tumor and immune cells and their effect on treatment (summarized in the last section of this review), the properties of the original tumor will affect the outcome. In inflamed tumors, immune cells are closely associated with tumor cells, while some tumors only display immune cells embedded in the surrounding stroma or lack immune cells completely. This will affect the immune-cell composition of early organoid cultures and the option to retain and expand these immune cells. If organoids are cultured over time, exogenous immune components need to be added. This provides more control of the specific cell types included, but the complexity of the patient-specific immune cell composition, containing numerous different cell types within the tumor and TME, cannot be easily replicated. The source of exogenous immune cells can be patient-specific PBMCs or allogeneic immune cells. Allogeneic cultures propose a challenge if major histocompatibility complex (MHC) molecules on organoid cells are recognized as non-self by donor T cells. This will result in high background killing compared to autologous systems, which may impair assay specificity. If antigen presentation to T cells are assayed, autologous co-cultures are needed, or alternatively, HLA matched immune cells.

Choosing the appropriate method for immune-organoid co-cultures will depend on the downstream assays. For therapies that exert their effect in hours, short organoid-immune cell co-cultures are fitting. Therapies with an effect over time pose an additional challenge, since longer co-cultures are required that support the viability of both tumor and immune cells, and the timing of the addition of immune components needs to be optimized.

Adding vasculature

Organoids in culture reach a limited size beyond which diffusion alone no longer allows exchange of oxygen, nutrient and metabolites, resulting in the formation of a central hypoxic core. This can be seen with organoids or spheroids measuring over 100-200 μm in size, while organoids with a diameter over 500 μm develop necrosis (28)(29). To overcome this, organoid vascularization and
perfusion are needed, which supports the growth of larger, viable organoids. On the other hand, organoids can be exploited to model hypoxia and necrosis in tumors (30).

Achieving vascularization of organoids remains a major challenge in the field to maintain organoid complexity and scale. Perfusion flow to the organoid through endothelial cell-lined channels could enable the generation of larger-sized organoids and prevent the formation of a necrotic core, but more complex organoids containing blood vessel-like structures can also be created.

Organoid angiogenesis is achieved by engraftment of organoids in vasculature-rich animal tissue, including chicken chorion allantois membrane (CAM) models, with host vasculature infiltrating the organoids (31). This was seen when human PSC-derived brain organoids were transplanted into adult mouse brain, which revealed extensive infiltration of host vasculature (32). Another study incorporated mesodermal progenitor cells into human tumor and neural organoids, which resulted in the formation of vascularized organoids in vitro (31). Vasculature can be added to in vitro co-cultures as layer-by-layer deposition of endothelial cells, or by selective removal of material to form tubular voids which are seeded with endothelial cells and connected to perfusion networks (33). Alternatively, using compartmentalized microfluidic chips, vascularization can be induced and guided by VEGF and hypoxia gradients in organoid-endothelial cell co-cultures (34)(33).

**Organoid on-a-chip**

One limitation of organoid cultures is the lack of reproducibility. Without scaffolds of physical constraints organoids show differences in size, shape, cell number and geometry. Organoid-on-a-chip models increase uniformity and control, thus enhancing their use for high-throughput screening and testing.

In 2D cultures or 3D organoid cultures, cells are usually not exposed to normal mechanical cues including fluid shear stress, tension and compression. The culture scaffolds, mimicking the ECM, provide structural and functional support for the cells and can promote survival, proliferation, and
differentiation (11). Microfluidics technology facilitates co-culture of tumor organoids with immune cells and other cell types in continuously perfused chambers and can recapitulate structural features of the environment. Moreover, sensors and actuators can be integrated with the microfluidic devices to enable precise monitoring and control (35).

A variety of microfluidics devices have been built to couple different tissue systems (36)(35). Nevertheless, incorporating multiple organoid types into single microchips introduces the challenge of finding optimized culture medium and physical conditions for the different organoids. Microfluidics systems have also successfully been used to study the migration of immune cells and their cross-talk and interaction with tumor cells (37).

**Complex organoids and immunotherapy**

An *ex vivo* assay to test immunotherapies requires a cancer-immune cell co-culture that enables the survival of all cell types, that matches the cellular distribution of the original tumor for a reasonable time frame and that captures the therapeutic effects of immune therapies. An advantage is the possibility to establish PDTOs which match the stage and the treatment history of patients in which novel drugs are tested. In a few recent studies, immune-enhanced tumor organoids have shown to be robust, relevant platforms to assess the efficacy of cancer immunotherapy, for the discovery of immune-oncology resistance mechanisms and for the identification of new combination therapy strategies (38).

**Antibody-based immunotherapy**

Antibody-based immunotherapy can specifically and directly target tumor cells to modify survival signals or deliver cytotoxic compounds. Alternatively, they can elicit immune responses by antibody mediated pathways or retarget T cells towards the tumor (39). Tumor organoids have, so far, mainly been used to study the efficacy and specificity of antibody-based immune checkpoint blockade-therapies. A recent study cultured PDTOs from surgically resected primary and metastatic tumors of several tumor types using the ALI method (24). Notably, these cultures maintained diverse
endogenous immune cell types (T- and B-cells, NK cells and macrophages) and non-immune stromal elements for weeks. Immune checkpoint blockade with anti-PD-1 and/or anti-PD-L1 resulted in the expansion and activation of tumor antigen-specific T cells within the organoid cultures and subsequent tumor killing. This shows that tumor-infiltrating lymphocytes (TILs) can remain functional in PDTOs, and that the PD-1/PD-L1 immune checkpoint can be recapitulated in these cultures.

In another study, Chakrabarti and colleagues established an autologous murine triple co-culture using gastric cancer or healthy organoids with DCs and CTLs (40). In short, gastric organoids were grown in Matrigel from healthy mice or from a transgenic mouse developing gastric tumors. Conditioned media from both models was used to pulse bone marrow-derived DCs. Subsequently, pulsed DCs and CTLs were co-cultured with either organoids in the presence of anti-PDL1 antibodies. Immune cells migrated to the organoids and prominent apoptosis was present only with tumor organoids treated with anti-PDL1 and co-cultured with DCs and CTLs pulsed with the tumor organoid-conditioned media. Using PDTOs and autologous patient-derived immune cells, this triple co-culture could be used as a pre-clinical model to test immunotherapy for individual patients.

Two other studies used mouse and patient-derived organotypic tumor spheroids in a collagen matrix microfluidics culture system. This culture contained autologous tumor-infiltrating immune cells and stroma. In the first study, the platform was used to profile secreted cytokines and identify novel effectors of immune checkpoint blockade therapy (22). Moreover, the study identified a combination therapy, PD-1-blockade with a TBK1/IKKe inhibitor, that counteracted resistance and enhanced the response to PD-1-blockade by helping to overcome an immunosuppressive TME. The second study performed a screen for small molecules capable of increasing the activity of T cells suppressed by PD-1 (41). Treatment of the tumor spheroids with the identified CDK4/6 inhibitor increased the levels of infiltrating T cells and synergized with anti-PD-1 blocking antibodies, resulting in increased anti-tumor activity. Another study instead used exogenous immune cells in a co-culture
with CRC spheroids/organoids (42). In this model, allogeneic T and NK cells rapidly infiltrated tumor spheroids resulting in immune mediated tumor cell apoptosis and spheroid destruction. They identified a pathway involved in tumor killing, NKG2D-MICA/B, that activated cytotoxic responses and further revealed that that anti-MICA/B and NKG2A antibodies were able to elicit immune-mediated destruction of CRC by stimulating the anti-tumor response. These examples show the potential of immune-tumor organoids for testing antibody mediated-therapy, identifying novel therapeutic targets and for the visualization and enhancement of immune cell migration and infiltration into tumors.

Bispecific antibodies can simultaneously bind two different antigens, thereby enhancing recognition or interact with a cytotoxic cell and a target tumor and bring them into close proximity leading to tumor cytotoxicity (43). Gonzalez-Exposito et al. used bispecific antibody therapy on organoid-immune cell co-cultures (44). The T cell bispecific antibody cibisatamab was designed to target CD3 on T cells and carcinoembryonic antigen (CEA) glycoprotein, often overexpressed in CRC. CRC organoids were cultured from metastatic chemotherapy resistant CRC patient biopsies in Matrigel. If biopsy samples were very small, they were first allowed to grow by engrafting them subcutaneously or under the kidney capsule of CD1 nude mice after which the CRC tumor was removed, depleted of mouse cells and organoids cultured in Matrigel. Co-cultures of eGFP tagged CRC organoids and CD8+ T cells purified from PBCMs were treated with cibisatamab and the growth of GFP positive CRC cells monitored. This strategy redirected T cells independently of their TCR specificity to CRC cells, mediating cancer cell recognition and killing. Using this model, the group showed that the CRC organoids displayed heterogeneity and plasticity of CEA expression, with CEA antigen loss contributing to resistance. The cells with low CEA expression displayed increased Wnt/β-catenin pathway activity. Since CEA expression can pharmacologically be enhanced by the inhibition of the WNT/β-catenin pathway, they suggested this as a potential strategy to increase the therapeutic benefit from cibisatamab (44). This complex organoid model proved beneficial for dissecting
mechanisms of immunotherapy resistance and identifying candidate biomarkers and combination therapies.

**Oncolytic virus-therapy**

Viruses that preferentially infect and replicate in tumor tissues while sparing the normal non-neoplastic host cells, offer an exciting immunotherapeutic approach (45). The anti-tumor effect of oncolytic viruses acts by directly lysing tumor cells and propagating the virus to nearby cells, and by triggering cytokine release and activation of the immune system (46)(47).

Two recent studies analyzed oncolytic virus infection and killing in tumor organoids. The first study demonstrated that tumor organoids can be used as predictive tools to screen for the sensitivity to oncolytic adenovirus therapy alone or in combination with chemotherapy (48). Oncolytic adenovirus displayed selectivity of replication in pancreatic PDTOs, but not normal tissue organoids grown in Matrigel from tissue derived from surgeries. Patient-specific adenoviral sensitivity was also seen, which mirrored the response in xenograph models as well as in primary tumors and metastases in nude mice, indicating that organoids are suitable models to explore pre-clinical responses to oncolytic viruses. Using glioblastoma brain cerebral organoids, Zhu et al. explored the efficacy and mechanism of the Zikavirus as an oncolytic virus in glioblastoma (GBM) (49). The Zikavirus targeted GBM stem cells rather than neural precursor cells through a SOX2-Integrin αvβ5 pathway, induced changes in the expression of immune-response genes and resulted in tumor cell death. Genetically modified Zikavirus with further optimized safety could potentially be used as oncolytic virus therapy against GBM. Although these studies show the promise of PDTOs for studying oncolytic virus infectivity and cytotoxicity, the oncolytic virus-initiated immune responses have not, to our knowledge, been studied in complex immune-organoids.

**Adoptive cell transfer-therapy**
In adoptive cell transfer therapy, circulating lymphocytes or TILs are collected, selected or modified, expanded and activated \textit{ex vivo} and re-administrated into patients, often in combination with immunostimulatory agents (3). T cells are either isolated based on their specificity for tumor antigens or are genetically modified. Genetic engineering of cells to produce a synthetic receptor, CAR, can specifically target an antigen on the cells and bypass MHC restriction (50).

CAR T and NK cell mediated cytotoxicity has been studied in tumor organoid models, which proved to be efficient platforms to evaluate CAR cell efficacy and tumor specificity. In one study, CRC organoids expressing HER2 derived from patient biopsies were cultured in Matrigel and anti-HER2 CAR T cells added (51). CAR T cells alone elicited only minimal killing, whereas a combination of CAR T cells and the inhibitor of apoptosis (IAP) antagonist birinapant significantly increased organoid death in a TNF-dependent manner. Interestingly, using this organoid model, killing could be demonstrated also in the absence of contact with the CAR T cell by a bystander effect of CAR T-cell-derived TNF, which could trigger apoptosis inside the organoids in the presence of birinapant. This combination therapy could initiate potent killing even with low numbers of CAR T cells reaching the tumor, and low penetration into tumors, thus overcoming one of the challenges for CAR T cell therapy. CRC organoids were also used to follow NK cell CAR-mediated cytotoxicity (52). Schnalzger et al. demonstrated efficient targeting of NK CAR cells directed toward the ubiquitous epithelial antigen EpCAM in CRC organoid models cultured in the presence of colonic primary fibroblasts. Using luciferase based and live cell imaging assays they further showed that neoantigen EGFRvIII-specific CAR NK cells efficiently killed EGFRvIII-expressing tumor organoids but not normal-tissue organoids. However, CARs against WNT ligand receptor FRIZZLED, upregulated in a subgroup of CRC, did not display tumor specific killing. This indicated that organoids may be used for rapid and individualized assessment of CAR-therapy antigen targeting and tumor cell specificity and allow live cell imaging of cell interactions and tumor toxicity over time. A crucial step for the success of CAR-based therapies is the recruitment of CAR cells to the tumor. Tumor organoids models, especially
those containing components of the TME, enable monitoring and enhancing the recruitment and penetration of CAR cells into tumor tissue and subsequent killing.

PDTOs can be used as a source of tumor reactive T cells, a culture platform to enrich them and to induce and assess the efficiency of tumor-specific T cell killing. Co-cultures of CRC and NSCLC organoids and autologous PBMCs were shown to enrich tumor-reactive T cells (25). After two weeks in co-cultures with successful CTL expansion, tumor killing was observed. This was not seen from the same patients when healthy organoids were generated, suggesting that cancer organoids are able to present cancer associated- or neo-antigens, triggering an effective anti-tumor T-cell response. TILs constitute a cell population actively engaged for destruction of specific tumor cells, since cells have already gained effector functions (3). TILs can be expanded ex vivo and infused back into the patient to generate more effective anti-cancer immune responses (53). CRC organoids co-cultured with TILs expanded from the same patient was used as an individualized pre-treatment test platform to predict patient response to neoadjuvant chemoradiotherapy (54). Cytotoxic killing was significantly higher in co-cultures that were generated from patients with a complete response to chemoradiotherapy, compared with co-cultures established from non-responders. This allowed stratification of patients and showed that the functionality of TILs can be used as robust biomarkers. Of great importance was the rapid establishment of tumor organoids and TILs within a clinically relevant timeline, 3 to 4 weeks from the diagnostic biopsy. Moreover, they further tested the platform for in vitro screening of the efficacy to rescue TIL function with checkpoint inhibition blockade and showed that the addition of anti-PD-1 antibody partially restored anti-tumor killing activity.

Taking the patient-specific, immune-organoid culture a step forward, a recent study describes a platform incorporating patient-specific, mature lymph node APCs within the organoid to generate adaptive immunity (55). This was done by a combined lymph node and melanoma organoid culture from the same patient and exposing matched blood T cells from the patient to the co-culture. This
brought into contact tumor cells with MHC I and MHC II-proficient nodal cells, allowing cross-presentation of antigens by the patient-specific APCs incorporated into the cultures. It permitted T cells to be activated and develop memory towards tumor neoantigens. These trained T cells showed effective killing of tumor cells in naïve tumor organoids from the same patient. Corresponding immune enhanced and non-enhanced patient derived organoids were then screened with check point inhibitors, showing increased killing in immune enhanced organoids. When the immune enhanced PDTOs response was compared with the clinical response of the patient to immunotherapy, they correlated in 85% of the cases. Although this study was performed with a modest number of patients it shows the potential of this complex organoid culture system for predicting and elucidating also adaptive immunotherapy responses.

Conclusions

Immunotherapy research drives the development of novel cancer treatments which, alone or in combination with other therapies, target immunomodulatory pathways and advance the control of cancer cells. There is growing interest in using patient-derived material to understand the dynamic interactions between the tumor and the immune system that influence therapy. Ex vivo systems that incorporate features of the TME and model immunotherapy responses could facilitate immunotherapy pre-clinical testing. There is great potential for PDTO-immune cell co-cultures to model mechanisms of immunotherapy efficiency and resistance. This addresses a major need in translational immunotherapy research.

Organoid cultures have shown promise for drug testing and development, studies of organ development, disease modelling and regenerative medicine. The main shortcoming of organoid technology for the use with immunotherapy prediction has been the lack of the stromal compartment. Moreover, the absence of blood vessels and immune cells equals loss of microenvironment influence on cancer behaviour. To circumvent these limitations, novel more complex organoid co-cultures of immune cells, vasculature and CAFs together with neoplastic cells
have successfully been developed. Nevertheless, the maintenance of heterogeneity in the tumor culture over time and the long-term preservation of stromal components still needs optimization. Additional work is required to estimate to what extent the different cell populations are maintained in the stroma when compared to the original tumor and to optimize culture media composition to support different cell types without selecting the outgrowth of only some clones.

Exposure of cells to physiological shear flow, mechanical stress, and substrate stiffness can have profound effects on cell and tissue physiology. Control over the size, shape and relative arrangement of different cell types within the organoids are important for reproducible quantitative studies required for robust drug screening and testing. This is being achieved using microfluidic devices.

The success rate of organoid cultures varies depending on tumor type and starting material. PDTOs can be cultured from fresh tumor tissue or biopsies. In some cases, patients receive treatments to shrink tumors prior to surgery, which may preclude organoid generation because of reduced tumor cell number or extended culturing time. For PDTO-cultures to be effective as clinical decision-making tools, it is crucial to keep the time needed to derive and expand the organoids to a minimum.

Numerous clinical trials are currently ongoing to determine the clinical application of PDTOs in personalized cancer therapy. Complex tumor organoid models have the potential to become tools for personalized immunotherapy validation, to test response and toxicity, to select patients for novel targeted therapies, and to support drug and treatment development in the setting of early clinical trials. Promising developments of complex organoids and their future adaptations can support clinical–translational efforts to develop novel combination treatments and ultimately personalized immunotherapy.

**Acknowledgements**

This work has been supported by European Research Council under the Horizon 2020 framework (https://erc.europa.eu), ERC-consolidator Grant (Agreement no. 681219), Jane and Aatos Erkko...
Foundation (Project no. 4705796), Academy of Finland and Digital Precision Cancer Medicine Flagship iCAN and the Magnus Ehrnrooth Foundation.

References


immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids.


**Figure legend**

**Figure 1. A)** Current applications of tumor-derived organoids. **B)** Complex immune organoids can be used as platforms to test immunotherapies and include tumor stroma, immune cells and vasculature in addition to tumor tissue. Organoids cultures in microfluidic devices provide flow and structure and permit the combination of different organoid types. Organoid interactions with the surrounding tissue and vasculature can also be provided by the engraftment of organoids into tissue like the chicken chorioallantoic membrane (CAM).
Patient-derived organoids for precision cancer immunotherapy

Mikaela Grönholm, Michaela Feodoroff, Gabriella Antignani, et al.

Cancer Res  Published OnlineFirst March 9, 2021.

Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-20-4026

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/early/2021/03/09/0008-5472.CAN-20-4026. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.